Author:
Li Huiqin,Cao Xiang,Gu Xinya,Dong Mengqi,Huang Lili,Mao Chenglu,Xia Shengnan,Yang Haiyan,Bao Xinyu,Yang Yongbo,Xu Yun
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Physiology,General Neuroscience
Reference43 articles.
1. Kuroda S, Houkin K. Moyamoya disease: Current concepts and future perspectives. Lancet Neurol 2008, 7: 1056–1066.
2. Ihara M, Yamamoto Y, Hattori Y, Liu W, Kobayashi H, Ishiyama H. Moyamoya disease: Diagnosis and interventions. Lancet Neurol 2022, 21: 747–758.
3. Sun Y, Zhou G, Feng J, Chen L, Liu G, Wang J, et al. Incidence and prevalence of moyamoya disease in urban China: A nationwide retrospective cohort study. Stroke Vasc Neurol 2021, 6: 615–623.
4. Cui TA, Ding ZK. Study on reversible anticholinesterase agents: Synthesis of derivatives of 1, 3, 2-dioxaphosphorinane 2-oxide. Yao Xue Xue Bao 1987, 22: 827–832.
5. Kundishora AJ, Peters ST, Pinard A, Duran D, Panchagnula S, Barak T, et al. DIAPH1 variants in non-east Asian patients with sporadic moyamoya disease. JAMA Neurol 2021, 78: 993–1003.